不同化疗方案治疗EGFR常见突变肺腺癌疗效的回顾性研究

魏雪武; 何韵婷; 郑明英; 周清

doi:10.3969/j.issn.1000-8179.2020.09.429

不同化疗方案治疗EGFR常见突变肺腺癌疗效的回顾性研究

A retrospective study on the efficacy of different chemotherapy regimens in lung adenocarcinoma patients harboring common EGFR mutations

摘要

摘要:
目的探究EGFR常见突变的肺腺癌患者最佳化疗方案。
方法回顾性收集2007年6月至2014年6月于广东省肺癌研究所就诊的晚期原发性肺腺癌患者的临床资料，分析不同化疗方案对于携带EGFR常见突变肺癌患者的疗效。
结果 205例携带EGFR常见突变的肺腺癌患者纳入研究，接受吉西他滨+铂类、培美曲塞+铂类和紫杉醇类+铂类方案治疗的患者分别为119、60和26例，客观缓解率及无进展生存期分别为25.2%、25.0%、30.8%及5.5、5.2、6.2个月，差异均无统计学意义（P=0.979；P=0.811）。
结论以吉西他滨、培美曲塞和紫杉醇类为基础的含铂化疗方案在携带EGFR常见突变肺腺癌患者中的疗效并无差异。

Abstract:
Objective: To investigate an optimal chemotherapy regimen for patients diagnosed with lung adenocarcinoma harboring common EGFR mutations.
Methods: Clinical data of 4, 021 patients diagnosed with advanced primary lung adenocarcinoma who were admitted to Guangdong Lung Cancer Institute from June 2007 to June 2014 were retrospectively collected. The efficacy of the standard chemotherapy regimen in patients diagnosed with luny adenocarcinoma harboring common EGFR mutations was analyzed.
Results: In total, 205 patients were included in the study, and 119, 60 and 81 patients received gemcitabine plus platinum, pemetrexed plus platinum, and paclitaxel plus platinum regimens, respectively. Statistical difference was not observed in the objective response rate (ORR, 25.2%, 25.0%, 30.8%, respectively) and progression free survival (PFS, 5.5, 5.2, 6.2 months, respectively) between these three treatment regimens (P=0.979, P=0.811).
Conclusions: Platinum-based chemotherapy regimens based on gemcitabine, pemetrexed, and paclitaxel have similar efficacy in patients diagnosed with advanced primary lung adenocarcinoma harboring common EGFR mutations.

HTML全文

参考文献(16)

施引文献

资源附件(0)